Clinical Trials Logo

Purpura, Thrombocytopenic clinical trials

View clinical trials related to Purpura, Thrombocytopenic.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT03866577 Terminated - Clinical trials for Immune Thrombocytopenic Purpura (ITP)

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

Start date: December 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic purpura (ITP) patients. The pharmacodynamics of the drug will be measured as platelet response in patients with ITP.

NCT ID: NCT02854059 Terminated - Clinical trials for Purpura, Thrombotic Thrombocytopenic

IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate safety and tolerability in patients diagnosed with asymptomatic antibody-mediated TTP with low ADAMTS13 activity after receiving single intravenous dose of IdeS.

NCT ID: NCT02050581 Terminated - Clinical trials for Idiopathic Thrombocytopenia Purpura

A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone

Dex/Rituxan
Start date: January 2011
Phase:
Study type: Observational

In this prospective and retrospective chart review, investigators will evaluate the response rates and duration of response for patients with relapsed and refractory idiopathic thrombocytopenic purpura (ITP) who have been treated with rituximab and repeated courses of dexamethasone. Investigators will also evaluate observed toxicities of the combination, and characteristics associated with response.

NCT ID: NCT02009761 Terminated - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Start date: December 18, 2013
Phase: Phase 1
Study type: Interventional

BI 655064 will be administered subcutaneously once weekly in patients with immune thrombocytopenic purpura (ITP) for up to 12 weeks.

NCT ID: NCT01938404 Terminated - Clinical trials for Thrombotic Thrombocytopenic Purpura

Octaplas Adult TTP Trial

Start date: June 6, 2017
Phase:
Study type: Observational

To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange, with a special emphasis on the occurrence of thromboembolic events (TEEs).

NCT ID: NCT01462916 Terminated - Clinical trials for Chronic Thrombocytopenic Purpura

Honey in Chronic Immune Thrombocytopenia

Start date: October 2014
Phase: N/A
Study type: Observational

Based on the assumption that honey may have an immunomodulatory effect, the aim of our present study will be to verify whether the intake of honey, as a natural substance, in patients with chronic Immune Thrombocytopenia (ITP) could affect the platelet number and hence could affect the bleeding severity. Thirty patients suffering from chronic ITP will be recruited from the Hematology Clinic of the Pediatric Hospital of Ain Shams University, Cairo, Egypt. The diagnosis of ITP will be based on the presence of isolated thrombocytopenia with a peripheral blood platelet count less than 100 x 109/L, and absence of any obvious initiating and/or underlying cause of the thrombocytopenia. Chronic ITP is defined as ITP for at least 12 months. The age of the patients will range from 5 to 15 years, and they will be of both sexes. This study was approved by the local Ethics Committee of the Pediatric Department of Ain Shams University, and an informed consent to participate in this study will be obtained from at least one parent of each patient. Furthermore, an ascent form will be obtained from each patient above 7 years of age.

NCT ID: NCT01433978 Terminated - Clinical trials for Idiopathic Thrombocytopenic Purpura

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Start date: March 26, 2012
Phase: Phase 3
Study type: Interventional

Core study: To compare the efficacy of avatrombopag (in addition to standard) of care to eltrombopag (in addition to standard of care) for the treatment of adult participants with chronic immune thrombocytopenia (idiopathic thrombocytopenic purpura [ITP]) as measured by durable platelet response. Open-label Extension Phase: To evaluate the safety and tolerability of long-term therapy with avatrombopag in participants with chronic ITP (cITP).

NCT ID: NCT00991939 Terminated - Clinical trials for Immune Thrombocytopenic Purpura

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

ITP^2
Start date: January 2010
Phase: Phase 3
Study type: Interventional

This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP). The primary hypothesis is that patients treated with high-dose dexamethasone will obtain a more durable remission than patients treated with prednisone.

NCT ID: NCT00953771 Terminated - Clinical trials for Thrombotic Thrombocytopenic Purpura

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

TTP
Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of the study is to find out if administration of danazol with plasma exchange and corticosteroids will reduce the number of plasma exchanges required to control Thrombotic Thrombocytopenic Purpura (TTP).

NCT ID: NCT00799773 Terminated - Clinical trials for Thrombotic Thrombocytopenic Purpura

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)

STAR
Start date: April 2009
Phase: Phase 3
Study type: Interventional

Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that causes blood clots to form in blood vessels. The main treatment for TTP is plasma exchange, in which affected patients receive transfusions of plasma, the liquid part of blood, from healthy donors. This study will examine the effectiveness of an antibody, rituximab, in combination with plasma exchange, at improving the immune response in people with TTP and decreasing the recurrence of TTP.